Table 1 Subject characteristics
Variables | Missing | Total (N = 64) | Vildagliptin (N = 40) | Glibenclamide (N = 24) | p |
|---|---|---|---|---|---|
Age (years) | 0 | 62 ± 9 | 61 ± 9 | 63 ± 10 | 0.28 |
Gender male n (%) | 0 | 43 (67) | 26 (65) | 17 (71) | 0.63 |
Smoking habit n (%) | 3 | 13 (22) | 7 (19) | 6 (26) | 0.72 |
CVD history n (%) | 2 | 13 (20) | 8 (20) | 5 (21) | 0.94 |
Hypertension n (%) | 2 | 43 (67) | 25 (63) | 18 (75) | 0.40 |
Disease duration (yrs) | 0 | 6.5 (3–10) | 7 (4–11) | 5 (1–10) | 0.30 |
Plasma glucose (mg/dl) | 0 | 154 ± 34 | 155 ± 36 | 150 ± 30 | 0.67 |
HBA1C (%) | 0 | 7.7 (7.4–8.1) | 7.7 (7.4–7.9) | 7.7 (7.5–8.1) | 0.57 |
HBA1C (mmol/mol) | 0 | 61 (57–65) | 61 (57–64) | 61 (58–65) | 0.57 |
Plasma C-peptide (ng/ml) | 8 | 2.67 (2.16–3.52) | 2.66 (2.07–3.48) | 2.78 (2.21–4.34) | 0.69 |
BMI (kg/m2) | 0 | 29.0 (26.2–33.9) | 29.1 (26.8–32.9) | 28.9 (25.4–34.1) | 0.94 |
Serum creatinine (mg/dl) | 2 | 0.8 (0.6–0.9) | 0.8 (0.6–0.9) | 0.8 (0.6–1.0) | 1.0 |
GFR (CKD-EPI) (ml/min/1.73 m2) | 3 | 96.0 ± 12.7 | 96.1 ± 11.8 | 96.0 ± 14.5 | 0.77 |
Total cholesterol (mg/dl) | 2 | 166.6 ± 30.3 | 168.5 ± 31.1 | 163.2 ± 29.8 | 0.56 |
HDL-cholesterol (mg/dl) | 2 | 45 (40–54) | 45 (41–51) | 45 (37–55) | 0.82 |
Tryglicerides (mg/ml) | 2 | 111 (71–155) | 100 (68–140) | 117 (78–1182) | 0.48 |
GGT (U/l) | 4 | 20 (16–32) | 19 (16–30) | 23 (14–36) | 0.63 |
AST (U/l) | 4 | 23 (19–28) | 23 (18–27) | 23 (19–28) | 0.89 |
ALT (U/l) | 4 | 27 (19–38) | 27 (19–38) | 28 (20–39) | 0.63 |
Uric acid (mg/dl) | 4 | 5.2 (4.5–6.0) | 5.2 (4.5–5.9) | 5.2 (4.4–6.3) | 0.76 |
EPC (n/106 events) | 0 | 38.0 (24.2–58.2) | 39.0 (24.0–58.2) | 37.5 (25.0–59.8) | 0.81 |
Therapies | |||||
Anti-hypertensive n (%) | 2 | 43 (67) | 25 (64) | 18 (75) | 0.40 |
Lipid-lowering n (%) | 2 | 44 (69) | 26 (67) | 18 (75) | 0.33 |
Antiplatelet n (%) | 2 | 30 (47) | 20 (51) | 10 (42) | 0.40 |
Metformin (mg/day) | 0 | 2000 (1750–2735) | 2000 (2000–2550) | 2000 (1700–2400) | 0.13 |